Angiodynamics vs PROCEPT BioRobotics
Angiodynamics reported revenue of $320 million in fiscal 2026, about the same as PROCEPT BioRobotics' $308 million in fiscal 2025. Angiodynamics' revenue grew 9.5% in its latest year, and PROCEPT BioRobotics' grew 37.2%. Angiodynamics had an operating margin of -12.5%, against -33.7% at PROCEPT BioRobotics. Free cash flow was $1 million at Angiodynamics and −$58 million at PROCEPT BioRobotics. Their fiscal years end in different months (May 31 and December 31), so the periods don't line up exactly.
Side by side
| Angiodynamics | PROCEPT BioRobotics | |
|---|---|---|
| Latest fiscal year | FY2026, May 31, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $320M | $308M |
| Revenue growth | 9.5% | 37.2% |
| Revenue growth a year, last 5 years | 1.9% | 109.1% |
| Gross margin | 54.6% | 63.7% |
| Operating margin | −12.5% | −33.7% |
| Net margin | −11.5% | −31.0% |
| Free cash flow | $1M | −$58M |
| Free cash flow margin | 0.2% | −18.9% |
| Return on capital | −24.6% | −65.4% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.6% | 6.6% |
| Last close | $11.87 | $23.80 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 4 of 9 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AngiodynamicsPROCEPT BioRobotics
Operating margin
Percent of revenue
AngiodynamicsPROCEPT BioRobotics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AngiodynamicsPROCEPT BioRobotics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Angiodynamics and PROCEPT BioRobotics pages.